Kornimate/medical-research-clean huggingface dataset:
outpatient pdd guided laser mediated destruction of bladder tumors

Conditions: Bladder Cancer

Summary: this study compare the efficacy of conventional photodynamic (pdd) guided transurethral bladder tumor resection in the operating theatre with outpatient pdd guided laser destruction of bladder tumors through flexible cystoscopes.

a prospective randomized two-part clinical trial comprising patients with recurrent pta low grade bladder tumors. study objectives and purpose: * 1st objective: to evaluate whether small pta bladder tumours can be removed with diode laser in an outpatient department with similar efficacy as by tur-bt resection in the operating theatre. * 2nd objective: to evaluate the patients experience of symptoms during laser treatment in the outpatient department (opd) using quality of life (qol) questionnaires (symptom evaluation) and visual analog scale score (pain evaluation). * 3rd objective: to evaluate whether patients prefer standard transurethral bladder tumor resection (tur-bt) in the operating theatre (ot) or laser treatment in the opd. * 4th objective: to evaluate the safety after laser treatment in the opd. efficacy: * 1st endpoint: proportion of patients with no tumor tissue in the bladder after 4 months and 12 months. * 2nd endpoint: visual analog scale score (pain evaluation) in patients having tumor removed by laser in the opd. general urinary problems and qol one week after the laser treatment. the danish validated questionnaire (qlq- bls24) from eortc will be used. * 3rd endpoint: patients preference for either opd laser treatment procedure or tur-bt in the ot as inpatient procedure. * 4th endpoint: character and severity of adverse events in relation to the outpatient treatment. study inclusion criteria: 1. ta low grade bladder tumor recurrences 2. up to a tumor size of 1,5 cm 3. up to 6 tumors 4. eligible patients for tur-bt exclusion criteria: 1. patients with porphyria 2. known hypersensitivity to hexvix® or porfhyrins 3. use of concomitant anticoagulants as marevan, marcoumar, and pradaxa 4. dementia 5. macroscopic hematuria 6. pregnant or breast feeding women 7. expected poor compliance estimated by the investigators 8. patients \< 18 years 9. patients who do not read or understand danish

Eligibility criteria:
inclusion criteria: 1. ta low grade bladder tumor recurrences 2. up to a tumor size of 1,5 cm 3. up to 6 tumors 4. eligible patients for tur-bt in ga exclusion criteria: 1. patients with porphyria 2. known hypersensitivity to hexvix® or porfhyrins 3. use of concomitant anticoagulants as marevan, marcoumar, and pradaxa 4. dementia 5. macroscopic hematuria 6. pregnant or breast feeding women 7. expected poor compliance estimated by the investigators 8. patients \< 18 years 9. patients who do not read or understand danish

Keywords: laser bladder cancer treatment outpatient tur-bt
effect of mouth rinses in oral malodor

Conditions: Halitosis

Summary: bad breath or halitosis is caused by specific gases originating from the mouth or the expired air. in most cases the pathology lies within the mouth and in this case receives the name pathologic halitosis of oral cause or oral malodor. the aim of this study is to evaluate the immediate (masking) and long term (therapeutic) effect of commercially available mouth rinses in the treatment of oral malodor. for this volunteers with oral malodor detected by organoleptic evaluation and confirmed by the increase level of sulphur compounds in their breath (vsc) will be asked to use a designated mouthwash. the breath parameters will be assessed at baseline and 15' after the first rinse (15 ml, during 1 minute) and over night at the end of a period of 3 weeks during which the volunteers rinsed twice a day (15 ml, 1 minute) with the assigned mouthwash. the short and long term effect of a stannous fluoride/amine fluoride/zinc rinse; a chlorhexidine/cetylpyridinium chloride/zinc product and a negative control(fluoride rinse and/or water) will be compared.


Eligibility criteria:
inclusion criteria: * caucasian * age ≥ 18 years * organoleptic score of breath ≥ 2 * vsc readings (sum of h2s and ch3sh by oralchroma) ≥ 120 ppb\* * intra-oral cause of bad breath * non-smokers * willing to participate and able to give written informed consent exclusion criteria: * ongoing dental treatment or any other medical treatment of the oral cavity * any known allergy to previously used oral hygiene products or any known allergy to any of the ingredients of the study products, which are used during the study * any pathological change of the oral mucosa * use of prohibited treatments / therapies and/or abuse of drugs, alcohol, etc * pregnancy or breastfeeding * active caries * acute sinusitis * severe oro-pharyngeal infections * on medications which can cause malodour * reduced salivary flow due to pathological reasons (e.g. sjögren syndrome) * situation considered not compatible with the study according to the investigator's opinion; the latter includes: patients eating very spicy food, persons under homeopathic therapy, patients who used antibiotics during the 2 months before the study, patients frequently using chewing gum, patients under corticosteroids or other serious medications. * patients unwilling to abstain from additional oral hygiene (only toothbrushing allowed) particularly mouthrinse, chewing gums, breath strips, etc

Keywords: oral malodor halitosis bad breath mouth rinses mouthwashes amine fluoride/stannous fluoride zinc ions chlorhexidine
a study on the safety of ozanimod exposure in pregnant women and their offspring

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis (ms) * currently or recently pregnant * reside in the united states, canada or germany. exclusion criteria: • exposure to other s1p therapies, cladribine, or mitoxantrone during the first trimester. other protocol-defined inclusion/exclusion criteria apply

Keywords: multiple sclerosis ozanimod pregnancy outcomes obstetric infant
rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.

Conditions: Prevention of Venous Thromboembolism

Summary: rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.


Eligibility criteria:
inclusion criteria: * objective diagnosis of colorectal cancer; * elective laparoscopic surgery for colorectal cancer * whatever the stage of cancer * antithrombotic prophylaxis with lmwh administered for 7±2 days after surgery exclusion criteria: * age \< 18 years * surgery for non-cancer disease * duration of surgery \< 45 min * conversion to open surgery * other indication for anticoagulant therapy * known cerebral metastases * kidney or liver failure * known hemorrhagic diathesis or high risk for bleeding * history of intracerebral bleeding or neurosurgery within 6 months * history of heparin induced thrombocytopenia * pregnancy or lactation * refusal of informed consent.
study on the prevention of dermal toxicity caused by regorafenib by traditional chinese medicine tdx105

Conditions: Hand and Foot Skin Reaction; Colorectal Cancer Stage IV

Summary: this is an preventive study to evaluate the preventive effect of traditional chinese medicine tdx105 on regorafenib induced dermatologic toxicities

this is an double blinded controlled preventive study to evaluate the preventive effect of this is an preventive traditional chinese medicine tdx105 plus urea ointment compared with placebo plus urea ointment on regorafenib induced dermatologic toxicities

Eligibility criteria:
inclusion criteria: 1. clinically confirmed colorectal cancer patients; 2. it is planned to use the targeted drug regorafenib for the first time, and the initial dose is 120mg/d; 3. performance status score ≤3; 4. age ≥18; 5, no intellectual and mental disorders, normal language expression ability, ability to judge their own symptoms 6. understand and agree to accept the treatment, and sign the informed consent. exclusion criteria: 1. patients with skin reactions affected by simultaneous use of other targeted drugs (sorafenib, sunitinib, fruquintinib, etc.), chemotherapy drugs (capecitabine, doxorubicin, etc.) or hand-foot radiotherapy; 2. patients with skin diseases such as eczema, psoriasis and tinea pedis at observed skin sites (namely hands and feet); patients with skin allergic diseases; 3. patients in the study who cannot cooperate with the continuation of this treatment; 4. sudden changes in the patient's condition affected and interfered with the researcher
study of brain imaging with nuclear technology in individuals with parkinsonian syndrome

Conditions: Parkinson's Disease; Parkinsonian Syndrome

Summary: this study assesses dopamine transporter density using single photon emission computed tomography (spect) brain imaging with an investigational radiopharmaceutical, \[123i\]ß-cit, in research participants with parkinson's disease.

the brain imaging is conducted at the institute for neurodegenerative disorders in new haven, connecticut. the imaging procedure occurs over a two day period. after a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with \[123i\]ß cit, an investigational radioactive material that localizes in the brain. twenty-four hours later study participants return to the institute for neurodegenerative disorders where an investigational scanning procedure is used to obtain spect (single photon emission computed tomography) images of the brain.

Eligibility criteria:
inclusion criteria: * at least 21 years of age * normal screening laboratory studies * at least two of the following: resting tremor, cogwheel rigidity, bradykinesia, and postural reflex impairment exclusion criteria: * pregnancy * significant medical disease including abnormalities found on screening

Keywords: parkinson diagnosis
radial shockwave versus ultrasound phonophoresis

Conditions: Supraspinatus Tendinitis

Summary: comparative study to compare the effect of radial shockwave versus ultrasound phonophoresis in management of chronic supraspinatus tendinitis consists of 3 groups exp1(shockwave treatment + conventional physical therapy) , exp2( ultrasound phonophoresis+ conventional physical therapy) and control group ( conventional physical therapy)


Eligibility criteria:
inclusion criteria:- bmi 18.5-24.9 * 18 years to 60 * with unilateral chronic supraspinatus tendinitis. * tenderness is found over the supraspinatus as it passes sub-acrominal and anterolateral. * the patient reported with positive jobe's test (empty can test) * the patient reported pain with active shoulder elevation in the scapular plane (eg: welders, plate workers, slaughterhouse workers and overhead playing athletes). * the patient reported pain with resisted isometric abduction exclusion criteria: * case reports, treatments after surgery, did not meet our specified outcome parameters, traumatic incidents, * partial tears at surgery * massive retracted tears at surgery * frozen shoulder. * rotator cuff tear. * glenohumeral or acromioclavicular arthritis

Keywords: shockwave , phonophoresis , supraspinatus tendinitis
spoon: sustained program for improving nutrition - colombia

Conditions: Exclusive Breast Feeding; Child Obesity; Malnutrition, Child

Summary: the primary goal of this study is to prevent undernutrition and obesity in peri-urban areas of colombia. this study is designed to evaluate the impact of promoting adequate feeding practices and the use of sq-lns (small quantity lipid-based nutrient supplements) on the nutritional status of infants and young children. the study will be conducted in peri-urban areas of pasto, colombia in conjunction with fundación saldarriaga concha and the colombian ministry of health and social protection.

spoon colombia is an innovative strategy to prevent undernutrition and obesity in children aged 0-24 months living in high-poverty areas of colombia. the spoon program aims to improve infant and young children feeding practices, including exclusive breastfeeding during a child's first six months and home-fortification with peanut-based sq-lns (small quantity lipid-based nutrient supplements) for children 6 to 24 months of age. the spoon intervention will randomly assign participants at the household level to one of three groups: a control group, treatment group 1, and treatment group 2. participants in the control group will receive the standard services provided by their local health clinics in addition to a supply of micronutrient powder. the powder consists of vitamins and minerals that are added to the child's food to increase his or her consumption of micronutrients. participants in treatment group 1 will receive group counseling and the sq-lns supplement instead of micronutrient powder. the group counseling program consists of various lessons for the children's caregivers about the importance of breastfeeding and providing high quality food with the sq-lns supplement. those assigned to treatment group 2 will receive all the services that those in treatment group 1 receive in addition to individualized counseling, where messages about nutrition and breastfeeding will be reinforced through home visits. comparing the three treatment arms will identify the marginal impact of the spoon program. for example, measuring the differences in outcomes between the participants in the control arm and in treatment group 1 will identify the impact of the spoon program package, which includes sq-lns and group counseling, compared to current government-provided services. measuring the differences between treatment group 1 and treatment group 2 will indicate the marginal impact of individualized counseling, and measuring the difference between the control arm and treatment group 2 will determine the combined impact of the spoon program combined with individualized counseling.

Eligibility criteria:
inclusion criteria: * participants must live in the defined intervention areas exclusion criteria: * any chronic disease or malformation * caretakers of the children plan on moving in the next 24 months
efficacy of iatrosedation and music therapy to attenuate dental anxiety

Conditions: Dental Anxiety

Summary: dental anxiety is a common problem encountered in the dental clinics that affect both patients and dentists. adequate management of the dental anxiety is critical for optimal treatment outcomes of the patient. in this clinical trial, a total of sixty patients were randomly assigned to three groups as follows: group 1, iatrosedation, group 2, music therapy, and group 3, control. patients in all of the three groups underwent dental crown preparation. . to measure the anxiety levels of the patients, heart rate was measured using a pulse oximeter, and verbal rating scale scores were assessed

dental anxiety is a common problem encountered in the dental clinics that affect both patients and dentists. adequate management of the dental anxiety is critical for optimal treatment outcomes of the patient. this study aims to assess the efficacy of different anxiety reduction techniques (iatrosedation and music therapy) in adult patients for dental crown preparations. in this clinical trial, a total of sixty patients were randomly assigned to three groups as follows: group 1, iatrosedation, group 2, music therapy, and group 3, control. patients in all of the three groups underwent dental crown preparation. to measure the anxiety levels of the patients, heart rate was measured using a pulse oximeter, and verbal rating scale scores were assessed. one-way anova, post hoc, and spearman's correlation was used to compare the mean values of the three groups.

Eligibility criteria:
inclusion criteria: * patients who were above 18 years of age * no systemic diseases * no previous dental treatment experience * showed willingness to participate exclusion criteria: * patients below the age of 18 years * medically compromised * previous history of dental treatment
biopsychological intervention in chronic fatigue syndrome - a pilot study

Conditions: Adolescent Chronic Fatigue Syndrome

Summary: this is a pilot study of a biopsychological intervention program for adolescent chronic fatigue syndrome. the program is related to cognitive behavioral therapy, which has been proven beneficial in this disorders, but includes other mental techniques, such as emotional control and metacognitive elaboration. the aim of this pilot study is to explore a) patients' experiences and b) possible positive effects on symptoms. we hypothesise that the intervention will be regarded feasible by the patients, and that fatigue score will improve during the intervention period.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic fatigue syndrome * significant school absenteeism * above 12 years of age and below 18 years of age exclusion criteria: * other diseases or life events that might explain chronic fatigue * bed-ridden
a comparison of the effects of krill oil and fish oil supplementation on muscle function in older adults

Conditions: Sarcopenia

Summary: the aim of the study is to compare the effects of krill oil and fish oil supplementation on muscle function in older adults. the secondary aim is to investigate the mechanisms underlying the beneficial effects previously observed.


Eligibility criteria:
inclusion criteria: * older adults (aged 60 years or older). bmi less than 30kg/m2 exclusion criteria: * participants (diagnosed and being treated for a pre-existing medical condition (cancer, kidney disease, liver disease, diabetes mellitus and cardiovascular disease, uncontrolled hypertension, gait disturbances limiting the ability to perform assessments of muscle function, dementia, affecting muscles known to use drugs (e.g., steroids). history of allergy to fish or fish oil and regular consumption of more than1portion of oily fish per week or use of fish oil or krill oil supplements will also be excluded.

Keywords: muscle mass strength omega-3 ageing
evaluating barriers to stroke screening and prevention in children with sickle cell disease

Conditions: Stroke Ischemic; Sickle Cell Disease

Summary: displace is a three part, multi-center u.s. based study to evaluate the barriers to stroke screening and prevention in children with sickle cell anemia (sca). in the united states, tcd (transcranial doppler ultrasound) is a proven method of screening children with sca for stroke. however, many children are not getting the screening they need. this study will examine the issues that hinder and help children get the screening at 28 different hospitals and sickle cell centers to improve care for all children with sickle cell anemia. the investigators will then plan a study (part 3) aimed to improve stroke screening and prevention in sickle cell anemia.

displace (dissemination and implementation of stroke prevention: looking at the care environment) is a multi-center, national nhlbi-funded grant to evaluate the real world implementation of the stop protocol in which transcranial doppler (tcd), a measure of cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia (sca). based on the stop (stroke prevention trial in sickle cell anemia) protocol, children identified as high risk of stroke by tcd are initiated on chronic red cell transfusion therapy (crct) for stroke prevention. children with normal tcd are screened annually from the age of 2 until they are 16 years of age. this will be a three-part study beginning with part 1 - a retrospective case record review followed by part 2 - a multi-level qualitative assessment of barriers and enablers to tcd screening and initiation of chronic red blood cell transfusions and later adding part 3 - a multi-center implementation clinical trial.the investigators will compare two implementation interventions to improve tcd screening. there are three aims of the grant and each aim is equivalent to the respective parts of the grant (i.e. part 1 covers 1 aim). there are a total 28 consortium sites. the medical university of south carolina is the lead institution for this study.

Eligibility criteria:
inclusion criteria: * age is \>2 and \<16 at time of review (from 2012-2016) * have documented sickle cell anemia * primary language is english * patient at a displace consortium institution caregiver characteristics: parent or guardian of patient who meets above criteria primary language is english has the cognitive capacity to complete questionnaires exclusion criteria: child characteristics: experiencing current acute complications of sickle cell disease requiring hospitalization or an acute care visit (e.g., pain crises, acute chest syndrome, acute cerebrovascular events/stroke or active infection/fever) caregiver characteristics: has a child experiencing current acute complication of sickle cell disease, such as pain crisis, acute chest syndrome, stroke, or infection.

Keywords: sickle cell anemia tcd screening dissemination implementation
urinary tract infection in pregnancy

Conditions: Urinary Tract Infections

Summary: * to describe the profile of uropathogenic e coli from egyptian pregnant women with utis and a symptomatic bacteriuria. * to determine the susceptibility pattern of our local isolated upec strains which is essential for optimal management of uti. * to evaluate the different virulence genes in upec isolates and their association with antibiotic resistance. * to track common upec serogroups. * to investigate the biofilm formation and the relationship between virulence genes and biofilm formation in upec strains isolated from patients.

urinary tract infection represents the most common bacterial infection in pregnancy and the third common cause of human infection after respiratory and intestinal infections. the infection can be life threatening and associated with serious complications. uti can be associated with defined symptoms'symptomatic' or without symptoms 'asymptomatic'. asymptomatic bacteriuria is defined as the presence of \>100000 colony forming units/ml of urine of a single pathogen in two consecutive midstream clean catch urine specimen or on catheterization specimen from an individual without signs or symptoms associated with urinary or genital organs. asymptomatic bacteriuria can lead to acute pyelonephritis in30%of pregnant women and complications such as early delivery, increase risk of hypertension, pre-eclampsia, low birth weight and postpartum endometritis. ecoli accounts for most cases of symptomatic and asymptomatic bacteriuria in women, representing70 _90 %of the cases. the important virulence factors of uropathogenic ecoli can be broadly divided into two groups :bacterial cell surface factors and secreted factors. the emergence of drug resistant microorganism among uropathogenic escherichia coli strains increases the serious threat to global health. ecoli often acquired genes coding for antibiotic resistance, beta-lactamase enzymes are the most frequent and play a key role, conferring resistance of bacteria to beta lactam antibiotic group such as penicillin and cephalosporins. therefore, knowledge regarding local prevalence of uropathogenic ecoli and antimicrobial resistance is essential for optimal management of uti.

Eligibility criteria:
inclusion criteria: * pregnant women who diagnosed through clinical examination and urine analysis. 3 groups : group 1 pregnant women with cystitis group 2 pregnant women with pyelonephritis group 3 pregnant women with asymptomatic bacteriuria exclusion criteria: * pregnant women on antibiotics _patients with any anatomical abnormalities in the urinary tract